Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological Cancers

Summary

This is an open-label, first-in-human, dose escalation study evaluating investigational drug PORPHYSOSMES (PS, pegylated porphyrin-lipid conjugate-containing nanoparticle suspension) and 64Cu-PORPHYSOMES (64Cu-PS, pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension) for PET/CT imaging assessments in patients with metastatic/advanced gynecological tumors.

Timeline

Start

2025-11-18

Primary completion

2026-11-18

Completion

2027-11-19

Drugs

Indications